Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on May 10, 2016. The filing serves to announce the company's financial results for the three-month period ended March 31, 2016. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the results for the quarter ended March 31, 2016.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies within the body of the 8-K. The document explicitly states that the information disclosed under Item 2.02 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other documents except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 10, 2016) for actual financial figures and operational highlights.
- Verify the company name discrepancy: The metadata lists "Cardiff Oncology, Inc.", but the filing is for Trovagene, Inc. (Note: Trovagene was later acquired by Cardiff Oncology).
- Confirm the status of the press release as "furnished" rather than "filed" for legal liability purposes.
- Check subsequent filings for any updates or corrections to the Q1 2016 results.